A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.

Front Immunol · 2021 · PMC8160380 · PMID 34054817

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In contrast, mIHC-F of hPD-L1-KLN205 tumor sections showed highly significant increases in CD8+ T cells and reductions in FoxP3+ Tregs and PD-L1 expression in PDI-1-treated mice compared with vehicle-treated mice ( Figures 5D, E ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.